Clinicopathological features of gastric neuroendocrine carcinomas and the roles of hASH1/HES1 in neuroendocrine differentiation of gastric cancers

胃神经内分泌癌的临床病理特征及hASH1/HES1在胃癌神经内分泌分化中的作用

基本信息

  • 批准号:
    17590316
  • 负责人:
  • 金额:
    $ 2.3万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

The current histologic classifications of gastric cancers define only carcinoids and small cell carcinomas in the neuroendocrine (NE) category. This study aimed to characterize the histologic and clinical features of high-grade gastric NE carcinomas of nonsmall cell type, tentatively named large cell neuroendocrine carcinoma (LCNEC). Tumors with histologic features suspicious of NE differentiation were selected by a histologic review of 2835 resected gastric cancers, and those with a NE phenotype in >50% and 1% to 50% tumor cells assessed by expressing chromogranin A and/or synaptophysin were defined as LCNEC and adenocarcinoma with neuroendocrine differentiation (ACNED), respectively. One hundred ninety-nine tumors were selected and of the 109 positive for chromogranin A and/or synaptophysin, 42 and 44 met the criteria for LCNEC and ACNED, respectively. Generally, LCNECs demonstrated less predominant NE morphology than carcinoids, and could be roughly divided into solid (30 cases), tubular (7 cases), and scirrhous (5 cases) subtypes with reference to their main growth pattern. The prognosis of LCNECs was significantly worse than that of conventional adenocarcinomas (P<0.0001). Thus, this study shows that the spectrum of gastric NE tumors is broader than has previously been recognized and LCNEC is not only a distinct histopathologic entity, but also a distinct clinical entity. Furthermore, the prognosis of ACNEDs was also significantly worse than that of adenocarcinomas (P<0.0001), and some ACNEDs might actually have been LCNECs, and survival analysis showed that >20% positivity of NE markers could be enough to characterize LCNEC, as long as light microscopic NE morphology was present in the tumor.
目前的胃癌组织学分类仅定义为神经内分泌(NE)类别的类癌和小细胞癌。本研究旨在探讨非小细胞型高级别胃NE癌的组织学和临床特征,暂定为大细胞神经内分泌癌(LCNEC)。通过对2835例切除的胃癌的组织学回顾,筛选出组织学特征可疑NE分化的肿瘤,其中NE表型在嗜铬粒素A和/或突触素表达的肿瘤细胞中分别占50%和1%~50%,分别定义为LCNEC和伴有神经内分泌分化的腺癌(ACNED)。在199个肿瘤中,嗜铬粒素A和/或突触素阳性的肿瘤中,42个和44个肿瘤分别符合喉癌和痤疮的诊断标准。一般来说,LCNEC的NE形态不如类癌明显,根据其主要生长方式可大致分为实性(30例)、管型(7例)和硬型(5例)。喉癌的预后明显差于常规腺癌(P&lt;0.0001)。因此,这项研究表明,胃NE肿瘤的范围比以前认识的更广泛,LCNEC不仅是一个独特的组织病理学实体,而且是一个独特的临床实体。此外,ACNEDs的预后也明显比腺癌差(P&lt;0.0001),有些ACNEDs实际上可能是LCNEC,生存分析表明,只要肿瘤中存在光镜下的NE形态,&gt;20%的NE标志物阳性就足以表征LCNEC。

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Gastric large cell neuroendocrine carcinomas : a distinct clinicopathological entity.
胃大细胞神经内分泌癌:一种独特的临床病理学实体。
Gastric Large Cell Neuroendocrine Carcinomas: A DistinctClinicopathological Entity
胃大细胞神经内分泌癌:一种独特的临床病理学实体
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Awaya N;Adachi A;Mori T;Kamata H;Nakahara J;Yokoyama K;Yamada T;Kizaki M;Sakamoto M;Ikeda Y;Okamoto S;Ueda M.;Chiba H et al.;Yamamoto Y;Shi-Xu Jiang et al.
  • 通讯作者:
    Shi-Xu Jiang et al.
Mash1 regulates the development of C cells in mouse thyroid glands
  • DOI:
    10.1002/dvdy.21018
  • 发表时间:
    2007-01-01
  • 期刊:
  • 影响因子:
    2.5
  • 作者:
    Kameda, Yoko;Nishimaki, Toshiyuki;Guillemot, Francois
  • 通讯作者:
    Guillemot, Francois
Telomere Length, Telomerase Activity, and Expression of Human Telomerase mRNA Component (hTERC) and Human Telomerase Reverse Transcriptase (hTERT) mRNA in Pulmonary Neuroendocrine Tumors
肺神经内分泌肿瘤中的端粒长度、端粒酶活性以及人端粒酶 mRNA 成分 (hTERC) 和人端粒酶逆转录酶 (hTERT) mRNA 的表达
Neuroendocrine neoplasms of the lung: A prognostic spectrum
  • DOI:
    10.1200/jco.2005.04.1202
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
    45.3
  • 作者:
    Asamura, H;Kameya, T;Nagai, K
  • 通讯作者:
    Nagai, K
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JIANG Shi-xu其他文献

JIANG Shi-xu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JIANG Shi-xu', 18)}}的其他基金

A study on the mechanisms underlying resistance acquisition of lung cancer for tyrosine kinase inhibitors
肺癌酪氨酸激酶抑制剂获得耐药机制的研究
  • 批准号:
    21590384
  • 财政年份:
    2009
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The roles of hASH1 gone in neuroendocrine differentiation of lung cancer and in the development of the lung
hASH1在肺癌神经内分泌分化及肺发育中的作用
  • 批准号:
    15590314
  • 财政年份:
    2003
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Elucidation of molecular pathogenesis and carcinogenesis in pulmonary large cell neuroendocrine carcinoma using patient derived organoids
使用患者来源的类器官阐明肺大细胞神经内分泌癌的分子发病机制和致癌作用
  • 批准号:
    22H03164
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of novel molecular targeted therapy and immunotherapy for high-grade neuroendocrine carcinoma of the lung and analysis of resistance mechanisms
肺高级别神经内分泌癌新型分子靶向治疗和免疫治疗进展及耐药机制分析
  • 批准号:
    22K09002
  • 财政年份:
    2022
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetic alterations and expressions of immune check point molecules in sinonasal neuroendocrine carcinoma
鼻窦神经内分泌癌中免疫检查点分子的基因改变及表达
  • 批准号:
    20K09731
  • 财政年份:
    2020
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigation of the pathogenesis of gastrointestinal tract neuroendocrine carcinoma through microscaled proteogenomic analysis
通过微观蛋白质组学分析研究胃肠道神经内分泌癌的发病机制
  • 批准号:
    20K17069
  • 财政年份:
    2020
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma
综合表观基因组方法将 ELF3 确定为 ASCL1 阳性神经内分泌癌的致癌调节因子
  • 批准号:
    20K16440
  • 财政年份:
    2020
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Search for new prognostic markers and establishment of personalised treatment for pulmonary high-grade neuroendocrine carcinoma based on a new subtype classification
基于新亚型分类的肺高级别神经内分泌癌寻找新的预后标志物并建立个体化治疗
  • 批准号:
    19K18213
  • 财政年份:
    2019
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a new treatment for high-grade neuroendocrine carcinoma of the lung targeting Stathmin1
开发针对 Stathmin1 的肺高级别神经内分泌癌新疗法
  • 批准号:
    19K07726
  • 财政年份:
    2019
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MicroRNA profiles to predict postoperative prognosis in patients with esophageal neuroendocrine carcinoma
MicroRNA谱预测食管神经内分泌癌患者术后预后
  • 批准号:
    18K08642
  • 财政年份:
    2018
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Neuroendocrine Factors in chemo-sensitivity for large cell neuroendocrine Carcinoma
神经内分泌因子在大细胞神经内分泌癌化疗敏感性中的作用
  • 批准号:
    18K08782
  • 财政年份:
    2018
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comprehensive analysis of gene mutation and expression profiles in neuroendocrine carcinoma of the stomach
胃神经内分泌癌基因突变及表达谱综合分析
  • 批准号:
    16K19960
  • 财政年份:
    2016
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了